About Fluxion Biosciences
Fluxion Biosciences is a company based in San Francisco (United States) founded in 2005 was acquired by Cell Microsystems in August 2023.. Fluxion Biosciences has raised $20.85 million across 9 funding rounds from investors including NIH, HHS and National Cancer Institute. Fluxion Biosciences offers products and services including CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder. Fluxion Biosciences operates in a competitive market with competitors including Guardant Health, GRAIL, MaxCyte, Thrive Earlier Detection and SQZBiotech, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20.85 M (USD)
in 9 rounds
-
Latest Funding Round
-
Investors
NIH
& 8 more
-
Employee Count
Employee Count
-
Acquired by
Cell Microsystems
(Aug 23, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Fluxion Biosciences
Fluxion Biosciences offers a comprehensive portfolio of products and services, including CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for isolating and growing single cells efficiently.
Enables physiological shear flow for drug discovery experiments.
Supports 3D cell culture for organoid and tissue research.
Offers accurate counting and viability assessment of cells.
Facilitates fast, enzyme-free tissue dissociation for analysis.
Unlock access to complete
Unlock access to complete
Funding Insights of Fluxion Biosciences
Fluxion Biosciences has successfully raised a total of $20.85M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Last Round
-
First Round
First Round
(13 Nov 2007)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2019 | Amount | Grant - Fluxion Biosciences | Valuation |
investors |
|
| Oct, 2012 | Amount | Series C - Fluxion Biosciences | Valuation |
investors |
|
| Oct, 2011 | Amount | Series C - Fluxion Biosciences | Valuation | Signet Healthcare Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Fluxion Biosciences
Fluxion Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and National Cancer Institute. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early stage venture fund investing in North America and Canada
|
Founded Year | Domain | Location | |
|
PE firm investing in North America and Europe
|
Founded Year | Domain | Location | |
|
Seed and early-stage venture capital firm investing in digital solutions for healthcare and energy industries.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Fluxion Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Fluxion Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Fluxion Biosciences Comparisons
Competitors of Fluxion Biosciences
Fluxion Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, MaxCyte, Thrive Earlier Detection and SQZBiotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Circulating tumor DNA is screened for early cancer detection.
|
|
| domain | founded_year | HQ Location |
Instrument systems for cell processing and modification are provided.
|
|
| domain | founded_year | HQ Location |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| domain | founded_year | HQ Location |
Cell therapies are developed using proprietary Cell Squeeze technology.
|
|
| domain | founded_year | HQ Location |
Provider of DNA sequencing for cancer detection
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Fluxion Biosciences
Frequently Asked Questions about Fluxion Biosciences
When was Fluxion Biosciences founded?
Fluxion Biosciences was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Where is Fluxion Biosciences located?
Fluxion Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Fluxion Biosciences a funded company?
Fluxion Biosciences is a funded company, having raised a total of $20.85M across 9 funding rounds to date. The company's 1st funding round was a Series C of $12M, raised on Nov 13, 2007.
What does Fluxion Biosciences do?
Provider of microfluidics-based tools for cellular analysis. It has three main systems which inlcude the IsoFlux Liquid biopsy system uses next-gen sequencing (NGS) to detect somatic variants from circulating tumor cells (CTCs) in blood. Fluxion also provides the reagent kits necessary for analysis with the IsoFlux system. The BioFlux system is a flow-through system that allows researchers to emulate in vivo shear flow conditions during drug discovery. The IonFlux system uses microfluidic technology for automated patch clamping. This system can be used to perform ligand binding, allosteric modulation, multiple agonists, and voltage- and temperature-sensitive assays for ion channel screening in drug discovery.
Who are the top competitors of Fluxion Biosciences?
Fluxion Biosciences's top competitors include Guardant Health, GRAIL and MaxCyte.
What products or services does Fluxion Biosciences offer?
Fluxion Biosciences offers CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder.
Who are Fluxion Biosciences's investors?
Fluxion Biosciences has 9 investors. Key investors include NIH, HHS, National Cancer Institute, Cell Microsystems, and NICHD.